Hualan Biological Engineering Inc.: history, ownership, mission, how it works & makes money

Founded in Xinxiang in 1992, Hualan Biological Engineering has grown from a regional plasma processor to a publicly listed Shenzhen company (002007.SZ) that set industry benchmarks with the country's first GMP certification for plasma products in 2009, forged an R&D alliance with the Chinese Academy of Sciences in 2010, and earned a spot on Forbes Asia's 200 Best Under A Billion in 2019; by December 12, 2025 its shares traded at CNY 15.28 with a market capitalization near CNY 27.92 billion, a total share capital of 1,827,456,666 shares and a proposed interim dividend of CNY 5 per 10 shares (total cash payout CNY 913,728,333), while operationally the company runs four production bases capable of producing over 200 million vaccine doses annually, allocates about 12% of revenue to R&D, reported CNY 4.38 billion in revenue for 2024 (an 18.02% decline from CNY 5.34 billion), derives over 60% of sales from human vaccines, earns roughly 30% of revenue from exports to more than 20 countries, holds a strategic cash allocation plan of up to CNY 7 billion for low‑risk investments, and continues to monetize its portfolio across human and animal vaccines, blood products and recombinant proteins while expanding patents and global reach-read on to explore its history, ownership, mission, operating model and revenue drivers in detail.

Hualan Biological Engineering Inc. (002007.SZ): Intro

• Founded: 1992, Xinxiang City, Henan Province, China
• GMP milestone: First company in China to receive GMP certification for plasma products in 2009
• R&D alliance: Strategic partnership formed with the Chinese Academy of Sciences in 2010
• Recognition: Included in Forbes Asia's 200 Best Under A Billion in 2019
• Shareholder returns: Proposed interim dividend in 2025 of CNY 5 per 10 shares

• Core revenue streams: plasma-derived therapeutics (immunoglobulins, albumin), vaccines, recombinant proteins and contract manufacturing/processing for third parties.
• Value chain integration: plasma collection & sourcing → GMP-accredited fractionation and purification → formulation, quality control and distribution to hospitals, clinics and distributors.
• Pricing drivers: product mix (high-margin immunoglobulins vs. commoditized albumin), regulatory approvals, reimbursement policies in China, and export opportunities.
• Margins & scale effects: GMP-certified large-scale production enables higher capacity utilization and margin improvements; R&D alliances and in-house capabilities shorten time-to-market for novel biologics.
• Capital allocation: reinvestment into capacity expansion and R&D balanced with shareholder returns (e.g., 2025 interim dividend proposal).

• Listing: Shenzhen Stock Exchange, ticker 002007.SZ.
• Ownership structure: a mix of institutional investors (domestic funds and insurers), retail shareholders and corporate insiders/management; governance follows China-listed company practices with board and supervisory committee oversight.
• Shareholder returns policy: demonstrated willingness to distribute cash (proposed CNY 5/10 shares interim dividend in 2025), indicating a cash-generative business and priority on investor returns alongside growth.

• Quality credentials: GMP certification for plasma products (2009) established early credibility for safety and regulatory compliance in biologics manufacturing.
• R&D partnerships: strategic alliance with the Chinese Academy of Sciences (2010) enhances pipeline development, biomolecular research and technology transfer capabilities.
• Product pipeline & differentiation: focus on improving formulations of immunoglobulins, expanding vaccine portfolio and developing recombinant products to capture higher-margin segments.

Hualan Biological Engineering Inc. (002007.SZ): History

• Established focus: blood products (albumin, immunoglobulins, coagulation factors) and vaccines.
• Listed on Shenzhen Stock Exchange under ticker 002007.SZ.
• Management-led growth with significant founder/management ownership supporting long-term strategy.

• Publicly listed with diversified ownership: institutional investors and retail/public shareholders alongside founders and management.
• Key executives: Mr. Li Jinming (Chairman), Mr. Fan Xiaohu (General Manager), Mr. Zhang Jian (Chief Financial Officer).
• As of June 30, 2025, total share capital: 1,827,456,666 shares.

• Plasma collection and fractionation into high-margin plasma-derived therapeutics sold to hospitals and distributors.
• Vaccine development, manufacturing and procurement contracts/market sales across public immunization programs and private channels.
• R&D pipeline for innovative biological drugs with potential future licensing, partnerships, and product launches.
• Capital allocation and cash management: approved CNY 7 billion of low-risk investments in 2025 to enhance financial flexibility and support operations/dividend policy.

• Expand blood products and vaccine portfolios and production capacity.
• Invest in R&D for novel biologics and leverage regulatory approvals to capture domestic market share.
• Maintain shareholder returns (interim dividend announcement June 30, 2025) while using balance-sheet strength for conservative investments.

Hualan Biological Engineering Inc. (002007.SZ): Ownership Structure

• Mission and values: advance public health, prioritize quality and innovation, expand global reach.
• R&D intensity: invests approximately 12% of annual revenue into research and development.
• Quality standards: manufacturing facilities operate under international Good Manufacturing Practice (GMP) guidelines.
• Strategic partnerships: collaborates with institutions such as the Chinese Academy of Sciences to bolster research capabilities.
• Global footprint: products available in over 20 countries, contributing to international vaccine supply chains.
• Shareholder returns: signaled focus on shareholder value with a significant interim dividend proposal in 2025.

Hualan Biological Engineering Inc. (002007.SZ): Mission and Values

• Human vaccines - development, manufacturing and commercialization of inactivated, recombinant and adjuvanted vaccines for routine immunization and outbreak response.
• Animal vaccines - products for livestock and companion animals addressing major veterinary infectious diseases, supporting China's animal husbandry and export markets.
• Blood products - plasma-derived therapeutics and related fractionation services for clinical use.

• R&D spending: ≈12% of revenue annually - funds discovery, process development, clinical studies and manufacturing optimization.
• Intellectual property: robust patent portfolio supporting novel formulations, processes and vaccine platforms.
• Collaboration: strategic partnerships with global health organizations, academic institutions and contract research bodies to accelerate development and broaden access.

• Commercial vaccine sales - routine immunization and seasonal vaccine campaigns are primary recurring revenues.
• Animal health sales - high-volume veterinary vaccine contracts and channel sales to agricultural partners.
• Blood product sales - clinical-grade plasma derivatives and associated services to hospitals and distributors.
• Contract manufacturing & technology services - third-party production and licensing of proprietary processes and formulations.

• National/provincial research contracts - multiple ongoing projects funded by central and regional authorities.
• Global health collaborations - agreements for knowledge exchange, clinical evaluation and distribution support in priority markets.
• Regulatory alignment - continuous investment in compliance to meet export and domestic regulatory requirements.

Hualan Biological Engineering Inc. (002007.SZ): How It Works

• Primary revenue streams: commercial sale of human vaccines, blood products (e.g., human serum albumin), recombinant proteins and other biologics.
• Market reach: domestic China market plus international exports (~30% of total revenue), supported by regulatory approvals and global distribution partnerships.
• R&D-driven growth: internal discovery, clinical development, and patent filings to broaden the product portfolio and protect innovations.

• Human vaccine segment: >60% of total sales (major products: hepatitis B, influenza, rabies) - estimated CNY 2,715,600,000 (approx. 62%).
• Blood products (incl. human serum albumin): ~20% - estimated CNY 876,000,000.
• Recombinant proteins and other biologics: ~10% - estimated CNY 438,000,000.
• Other/ancillary sales: ~8% - estimated CNY 350,400,000.

• High-volume vaccine production lines with seasonal and routine immunization demand (hepatitis B, influenza, rabies).
• Blood product manufacturing and purification capacity for human serum albumin and related plasma derivatives.
• Commercialization infrastructure for domestic hospital/CDC channels and export logistics to international partners.
• Investment in R&D and patent filings to secure exclusivity and expand into innovative biological drugs and next‑gen vaccines.

• Expanding blood product and vaccine pipelines, plus clinical advancement of innovative biologics.
• Increasing export penetration to sustain ~30% international revenue contribution and diversify market risk.
• Leveraging patent portfolio and manufacturing scale to improve margins and fend off competition.

Hualan Biological Engineering Inc. (002007.SZ): How It Makes Money

• Core revenue streams: plasma products (fractionated plasma-derived therapies), influenza vaccines (seasonal and pandemic formulations), other vaccines, diagnostic reagents and biological contract manufacturing.
• Geographic reach: domestic leadership in China with product registrations and exports to over 20 countries across Asia, Africa and Latin America.
• R&D-to-commercialization pipeline: investments in innovative biologics and process improvements that enable higher-margin proprietary products.

• How revenue is captured:
  • Direct product sales to hospitals, CDCs and distributors (vaccines & plasma products).
  • Government procurement and bulk vaccine tenders (stable, large-volume contracts).
  • Exports and international tenders augment domestic sales and improve utilization of production lines.
  • Fee-for-service and contract manufacturing agreements for third parties.
• Margin drivers:
  • Scale in plasma fractionation and vaccine manufacturing reduces unit costs.
  • Proprietary formulations and registered products command higher ASPs (average selling prices).
  • R&D commercialization (new biologics) offers future high-margin uplift.